PD-1 inhibitor combined with apatinib modulate the tumor microenvironment and potentiate anti-tumor effect in mice bearing gastric cancer

• DOI: 10.1016/j.intimp.2021.107929
• Publication Date: 2021-07-31T05:31:33Z
• Authors: Hao Chen; Tao Jiang; Fangyu Lin; Hongdan Guan; Jianwei Zheng; Qing Liu; Bing Du; Yeyuan Huang; Xiaoyan Lin
• Keywords: Apatinib

To explore the effect of programmed death 1 (PD-1) inhibitor combined with apatinib on immune regulation and efficacy therapy in mice bearing gastric cancer (MBGC), to provide a research basis for enhancing benefit immunotherapy advanced (AGC). MBGC were divided into normal saline group (group NS), A), PD-1 inhibitors B) C). Tumor inhibition rates calculated. Cytokine levels expression cells molecules detected, pathological manifestations tumor tissues observed. Group C had smallest volume (115.17 ± 16.08 mm3) rate 89.4% 0.69%, significantly increased CD4+T CD8+T (P < 0.01), down-regulated proportion myeloid-derived suppressor (MDSCs) (PD-1+CD8+T) 0.01). There was no difference PD-1+CD8+T, cells, MDSCs between groups B C. Besides, combination interleukin-2 (IL-2), interferon-gamma (IFN-γ), necrosis factor-ɑ (TNF-ɑ) tissue serum. We also found that anti-angiogenic ligand-1 (PD-L1) levels, vascular endothelial growth factor receptor 2 (VEGFR-2) induced an increase extent necrosis. may help improve treatment outcomes survival benefits patients AGC.